ArticleInvestigative ophthalmology & visual science2025
Yes-Associated Protein (YAP) Is Associated With Disease Severity and Visual Prognosis in Epiretinal Membrane.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate whether Yes-associated protein (YAP), a key mechanotransduction effector, is associated with disease severity, surgical difficulty, and postoperative outcomes in epiretinal membrane (ERM) and to explore its prognostic relevance. Methods: This prospective study enrolled patients undergoing vitrectomy for ERM. Pre- and postoperative best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) parameters, including ERM stage, central subfield thickness (CST), inner retinal irregularity index (IRII), and ellipsoid zone disruption (EZD), were evaluated. Surgical grading of internal limiting membrane (ILM) adherence (SGIA) was applied to assess ILM adhesion and surgical difficulty. ERMs were analyzed by immunohistochemistry (IHC) and quantitative polymerase chain reaction (qPCR), and vitreous cytokines were also analyzed. Results: Among 152 patients with ERM stages ≥ 2, 26.3% were classified as stage 2, 42.1% as stage 3, and 31.6% as stage 4. Advancing ERM stage was significantly associated with poorer BCVA, higher SGIA grade, and worsening OCT parameters. YAP expression (by qPCR and IHC) and vitreous TGF-β1 levels progressively increased with ERM stage. YAP on IHC showed stronger associations with postoperative CST, postoperative IRII, and both pre- and postoperative EZD, whereas TGF-β1 was more strongly linked to preoperative CST and IRII. YAP also correlated independently with SGIA grade. Multivariate analysis identified YAP expression and SGIA grade as independent predictors of postoperative BCVA and visual improvement. Conclusions: ILM adhesion and surgical difficulty increase with ERM progression. YAP expression reflects ERM stage, ILM adhesion-related surgical complexity, postoperative retinal remodeling, and visual outcomes, independent of TGF-β pathways. These findings highlight YAP-mediated mechanotransduction as a key contributor to ERM pathophysiology and prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.